Quotient Sciences Quotient Sciences

X

Find the latest Drugs in Development and Pipeline Prospector News of Lonza Capsugel.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Lonza Capsugel
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
412, Mt. Kemble Ave Suite 200S, Morristown, NJ 07960
Telephone
Telephone
201-316-9200

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Lonza will manufacture the ACU193 (sabirnetug) drug substance, the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer’s disease.


Lead Product(s): Sabirnetug

Therapeutic Area: Neurology Product Name: ACU193

Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Acumen Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 04, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the expanded collaboration, Vaxcyte will utilise existing Lonza infrastructure to advance clinical development and commercialization of Vaxcyte’s PCV candidates, VAX-24, a 24-valent pneumococcal conjugate vaccine and VAX-31, in both the adult and pediatric populations.


Lead Product(s): 24-valent Pneumococcal Conjugate Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24

Highest Development Status: Phase IIProduct Type: Vaccine

Partner/Sponsor/Collaborator: Vaxcyte

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration October 16, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration aims to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, focusing on the VX-880 (STx-02) and VX-264 programs in clinical trials.


Lead Product(s): STx-02

Therapeutic Area: Endocrinology Product Name: VX-880

Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

Recipient: Vertex Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration supports the development and manufacturing of ABL Bio’s new bispecific antibody product by leveraging Lonza’s GS Xceed® expression system which includes GS PiggyBac®, a highly efficient transposon-based gene integration technology.


Lead Product(s): Bispecific Antibody

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: ABL Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 04, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lonza will integrate Simris’ antibody-drug conjugate payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines.


Lead Product(s): Antibody-Drug Conjugate

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Recipient: Simris Group

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the new agreement, McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates and antibody-drug conjugate.


Lead Product(s): Antibody-drug Conjugate

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: McSAF

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaborations will enable the integration of McSAF Inside® and Cristal Therapeutic's CliCr®, into the Lonza Bioconjugation Toolbox and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates and antibody-drug conjugate.


Lead Product(s): Antibody-drug Conjugate

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: Cristal Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 17, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Lonza will support the development and manufacturing of CTIM-76, a CLDN6 x CD3 bispecific antibody clinical candidate. The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6.


Lead Product(s): CTIM-76

Therapeutic Area: Oncology Product Name: CTIM-76

Highest Development Status: PreclinicalProduct Type: Large molecule

Recipient: Context Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 09, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology; a linear, covalently closed DNA vector, produced using an enzymatic manufacturing process.


Lead Product(s): mRNA-based Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Vaccine

Partner/Sponsor/Collaborator: Touchlight

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration is aimed to manufacture W0180, an innovative monoclonal antibody discovered by Pierre Fabre targeting the VISTA checkpoint, currently being investigated as a single agent and in combination with pembrolizumab in Phase I clinical trial in various solid tumors.


Lead Product(s): W0180,Pembrolizumab

Therapeutic Area: Oncology Product Name: W0180

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Pierre Fabre

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 15, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY